TITLE

Hectorol

PUB. DATE
March 2011
SOURCE
Pharmaceutical Representative;Mar2011, Vol. 41 Issue 3, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article mentions the approval of Genzyme's Hectorol injection to treat secondary hyperparathyroidism in patients with chronic kidney disease (CKD) on dialysis.
ACCESSION #
59218732

 

Related Articles

  • FDA OKs Drug For Renal Failure And Parathyroid Cancer.  // RN;May2004, Vol. 67 Issue 5, p86 

    Reports on the United States Food and Drug Administration's approval of cinacalcet or Sensipar to treat secondary hyperparathyroidism in patients with chronic kidney diseases on dialysis and hypercalcemia in patients with parathyroid cancer. Characteristics of the drug; Results of the clinical...

  • Emergency Treatment for Opioid Overdose Approved.  // Journal of Gerontological Nursing;Jun2014, Vol. 40 Issue 6, p6 

    The article reports on the approval of Kaleo's Evzio prescription drug by the U.S. Food and Drug Administration (FDA) for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.

  • New AMD treatment licensed. McCormick, Emily // Optometry Today;12/14/2012, Vol. 52 Issue 24, p6 

    The article reports that Bayer's Eylea injection treatment for wet age-related macular degeneration (AMD) has been approved for use in Europe and will be subjected for appraisal of the National Institute of Health and Clinical Excellence (NICE).

  • Simponi Approved for Ulcerative Colitis.  // Monthly Prescribing Reference;Jun2013, Vol. 29 Issue 6, pA30 

    The article informs that simponi injection has been approved for the treatment of ulcerative colitis in adult patients who have demonstrated corticosteroid dependence.

  • Neurology.  // PharmaWatch: CNS;January 2004, Vol. 3 Issue 1, p4 

    Reports on Janssen Pharmaceutica NV's launch of Risperdal Consta injectable respiridone in the United States. Intramuscular injection of the drug; Estimated number of Americans suffering from schizophrenia; Food and Drug Administration's approval of the drug in 2003.

  • New molecular entities.  // Formulary;Jul2005, Vol. 40 Issue 7, p210 

    Provides information on drugs that were approved by the United States Food and Drug Administration. Exenatide injection; Tigecycline antibiotic; Tipranavir.

  • FDA actions.  // Clinical Cardiology Alert;Feb2012 Pharmacology Watch, p2 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) for the use of pasireotide diaspartate injection in treating patients with Cushing's disease who are not surgery candidates and for whom surgery has not effective.

  • FDA actions.  // Primary Care Reports;Feb2013 Pharmacology Watch, p2 

    The article reports on the approval of the pasireotide diaspartate injection marketed by Novartis AG as Signifor by the U.S. Food and Drug Administration (FDA) for the treatment of Cushing's disease in patients who are not in line for surgery and for those patients whose surgery has not worked.

  • Makena.  // Pharmaceutical Representative;Mar2011, Vol. 41 Issue 3, p11 

    The article reports on the decision of the U.S. Food & Drug Administration (FDA) to approve Makena injection to reduce the risk of preterm delivery before 37 weeks of pregnancy.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics